IMDX (Insight Molecular Diagnostics) Insider Ownership: 22.89 % (As of Jul. 25, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

IMDX Insight Molecular Diagnostics Inc IMDX
49 GF Score
Price $4.74
GF Value $1.25
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Insight Molecular Diagnostics Insider Ownership?

Insight Molecular Diagnostics IMDX -4.44% 49 Insider Ownership is 22.89 % as of Jul. 25, 2026. GuruFocus rates IMDX with a GF Score™ of 49/100 and a GF Value™ of $1.25 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Insight Molecular Diagnostics's insider ownership is 22.89%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Insight Molecular Diagnostics's Institutional Ownership is 60.28%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Insight Molecular Diagnostics's Float Percentage Of Total Shares Outstanding is 49.07%.

Insight Molecular Diagnostics Insider Ownership Historical Data

* Premium members only.

The historical data trend for Insight Molecular Diagnostics's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Insight Molecular Diagnostics Insider Ownership Chart

Insight Molecular Diagnostics Historical Data

The historical data trend for Insight Molecular Diagnostics can be seen below:

2025-06-30 2025-07-31 2025-08-31 2025-09-30 2025-10-31 2025-11-30 2026-01-31 2026-02-28 2026-05-31 2026-06-30
Insider Ownership 25.18 25.22 25.20 25.20 25.20 25.33 25.33 22.54 22.62 22.89
IMDX
49GF Score
Insight Molecular Diagnostics Inc IMDX
Insider Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Insight Molecular Diagnostics Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Frequently Asked Questions Learn more about Insider Ownership →
What does a Insider Ownership of 22.89 % mean?
Insight Molecular Diagnostics (IMDX) has a Insider Ownership of 22.89 % as of Jul. 25, 2026. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Insight Molecular Diagnostics and its competitors.
Is Insight Molecular Diagnostics' Insider Ownership too high?
Insight Molecular Diagnostics' current Insider Ownership is 22.89 %. Overall, Insight Molecular Diagnostics has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Insight Molecular Diagnostics' Insider Ownership compare to XGN and BDSX?
Insight Molecular Diagnostics' Insider Ownership of 22.89 % can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Insider Ownership for a Medical Diagnostics & Research company?
A good Insider Ownership depends on the Medical Diagnostics & Research industry context. However, Insider Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Insider Ownership mean?
A high Insider Ownership can signal that a stock is expensive relative to its fundamentals. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Insight Molecular Diagnostics and its competitors. Insight Molecular Diagnostics's current Insider Ownership is 22.89 %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Insight Molecular Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Insight Molecular Diagnostics (IMDX) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.25, compared to a current price of $4.74 — trading 279.2% above its estimated fair value. The current Insider Ownership is 22.89 %. Insight Molecular Diagnostics' overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Insider Ownership calculated?
Insider Ownership is calculated from a company's financial statements. For Insight Molecular Diagnostics (IMDX), the current Insider Ownership is 22.89 % as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Insight Molecular Diagnostics (IMDX) Overvalued in 2026?

Based on GuruFocus' analysis, Insight Molecular Diagnostics stock appears to be overvalued. The current stock price of $4.74 is trading 279.2% above its estimated GF Value™ of $1.25. GuruFocus considers Insight Molecular Diagnostics to be Significantly Overvalued.

Key valuation signals for IMDX:

  • Insider Ownership: 22.89 %
  • GF Value™: $1.25 vs. price of $4.74 (279.2% above fair value)
  • GF Score™: 49/100 with 7 warning signs

No single metric tells the full story. See the IMDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Insight Molecular Diagnostics Business Description

Other Exchanges 0KCC:UK7OC0:Germany
Address 2 International Plaza Drive, Suite 510, Nashville, TN, USA, 37217
Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx. The company geographically operates in the United States, the United Kingdom, Europe, and the Asia-Pacific regions, with maximum revenue generated from the USA.
49GF Score

Get the complete analysis for IMDX

Insider Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.74
Price
$1.25
GF Value